
Title:
Atropine
Text:
pharmaceutical drug
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}AtropineClinical dataTrade namesAtropen, othersOther namesDaturin [1]AHFS/Drugs.comMonographMedlinePlusa682487License data
US DailyMed: Atropine
Pregnancycategory
AU: A

Routes ofadministrationBy mouth, intravenous, intramuscular, rectalDrug classantimuscarinic (anticholinergic)ATC codeA03BA01 (WHO) S01FA01 (WHO)Legal statusLegal status
US: ℞-only 
Pharmacokinetic dataBioavailability25%Metabolism≥50% hydrolysed to tropine and tropic acidOnset of actionc. 1 minute[2]Elimination half-life2 hoursDuration of action30 to 60 min[2]Excretion15–50% excreted unchanged in urineIdentifiers
IUPAC name
(RS)-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate
CAS Number51-55-8 YPubChem CID174174IUPHAR/BPS320DrugBankDB00572 YChemSpider10194105 YUNII7C0697DR9IKEGGD00113 YChEBICHEBI:16684 YChEMBLChEMBL9751 NCompTox Dashboard (EPA)DTXSID4020113 ECHA InfoCard100.000.096 Chemical and physical dataFormulaC17H23NO3Molar mass289.375 g·mol−13D model (JSmol)Interactive image
SMILES
CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)C(CO)c2ccccc2

InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16? YKey:RKUNBYITZUJHSG-SPUOUPEWSA-N Y
.mw-parser-output .nobold{font-weight:normal} NY (what is this?)  (verify)
Atropine is a tropane alkaloid and anticholinergic medication used to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate, and to decrease saliva production during surgery.[3] It is typically given intravenously or by injection into a muscle.[3] Eye drops are also available which are used to treat uveitis and early amblyopia.[4][5] The intravenous solution usually begins working within a minute and lasts half an hour to an hour.[2] Large doses may be required to treat some poisonings.[3]
Common side effects include a dry mouth, large pupils, urinary retention, constipation, and a fast heart rate.[3] It should generally not be used in people with angle closure glaucoma.[3] While there is no evidence that its use during pregnancy causes birth defects, that has not been well studied.[6] It is likely safe during breastfeeding.[6] It is an antimuscarinic (a type of anticholinergic) that works by inhibiting the parasympathetic nervous system.[3]
Atropine occurs naturally in a number of plants of the nightshade family, including deadly nightshade (belladonna), Jimson weed, and mandrake.[7] It was first isolated in 1833,[8]
It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[3][10]

Contents

1 Medical uses

1.1 Eyes
1.2 Heart
1.3 Secretions
1.4 Poisonings
1.5 Irinotecan induced diarrhea


2 Side effects
3 Contraindications
4 Chemistry
5 Pharmacology
6 History
7 Natural sources
8 Synthesis

8.1 Biosynthesis


9 Name
10 See also
11 References
12 External links



Medical uses[edit]
  An ampoule containing atropine injection 1mL/0.5mg
Eyes[edit]
Topical atropine is used as a cycloplegic, to temporarily paralyze the accommodation reflex, and as a mydriatic, to dilate the pupils. Atropine degrades slowly, typically wearing off in 7 to 14 days, so it is generally used as a therapeutic mydriatic, whereas tropicamide (a shorter-acting cholinergic antagonist) or phenylephrine (an α-adrenergic agonist) is preferred as an aid to ophthalmic examination.
In refractive and accommodative amblyopia, when occlusion is not appropriate sometimes atropine is given to induce blur in the good eye.[11] Evidence suggests that atropine penalization is just as effective as occlusion in improving visual acuity.[12] Antimuscarinic topical medication is effective in slowing myopia progression in children; accommodation difficulties and papillae and follicles are possible side-effects.[13] All doses of atropine appear similarly effective, while higher doses have greater side effects.[14] The lower dose of 0.01% is thus generally recommended due to fewer side effects and potential less rebound worsening when the atropine is stopped.[14][15]

Heart[edit]
Injections of atropine are used in the treatment of symptomatic or unstable bradycardia.
Atropine was previously included in international resuscitation guidelines for use in cardiac arrest associated with asystole and PEA, but was removed from these guidelines in 2010 due to a lack of evidence for its effectiveness.[16]  For symptomatic bradycardia, the usual dosage is 0.5 to 1 mg IV push, may repeat every 3 to 5 minutes up to a total dose of 3 mg (maximum 0.04 mg/kg).[17]
Atropine is also useful in treating second-degree heart block Mobitz type 1 (Wenckebach block), and also third-degree heart block with a high Purkinje or AV-nodal escape rhythm.  It is usually not effective in second-degree heart block Mobitz type 2, and in third-degree heart block with a low Purkinje or ventricular escape rhythm.[citation needed]
Atropine has also been used in an effort to prevent a low heart rate during intubation of children; however, evidence does not support this use.[18]

Secretions[edit]
Atropine's actions on the parasympathetic nervous system inhibit salivary and mucus glands. The drug may also inhibit sweating via the sympathetic nervous system.  This can be useful in treating hyperhidrosis, and can prevent the death rattle of dying patients. Even though atropine has not been officially indicated for either of these purposes by the FDA, it has been used by physicians for these purposes.[19]

Poisonings[edit]
Atropine is not an actual antidote for organophosphate poisoning. However, by blocking the action of acetylcholine at muscarinic receptors, atropine also serves as a treatment for poisoning by organophosphate insecticides and nerve agents, such as tabun (GA), sarin (GB), soman (GD), and VX. Troops who are likely to be attacked with chemical weapons often carry autoinjectors with atropine and an oxime, for rapid injection into the muscles of the thigh.  In a developed case of nerve-gas poisoning, maximum  atropinization is desirable. Atropine is often used in conjunction with the oxime pralidoxime chloride.
Some of the nerve agents attack and destroy acetylcholinesterase by phosphorylation, so the action of acetylcholine becomes excessive and prolonged. Pralidoxime (2-PAM) can be effective against organophosphate poisoning because it can re-cleave this phosphorylation.  Atropine can be used to reduce the effect of the poisoning by blocking muscarinic acetylcholine receptors, which would otherwise be overstimulated, by excessive acetylcholine accumulation.
Atropine or diphenhydramine can be used to treat muscarine intoxication.

Irinotecan induced diarrhea[edit]
Atropine has been observed to prevent or treat irinotecan induced acute diarrhea.[20] 

Side effects[edit]
Adverse reactions to atropine include ventricular fibrillation, supraventricular or ventricular tachycardia, dizziness, nausea, blurred vision, loss of balance, dilated pupils, photophobia, dry mouth and potentially extreme confusion, deliriant hallucinations, and excitation especially among the elderly. These latter effects are because atropine is able to cross the blood–brain barrier. Because of the hallucinogenic properties, some have used the drug recreationally, though this is potentially dangerous and often unpleasant.[medical citation needed]
In overdoses, atropine is poisonous. Atropine is sometimes added to potentially addictive drugs, particularly antidiarrhea opioid drugs such as diphenoxylate or difenoxin, wherein the secretion-reducing effects of the atropine can also aid the antidiarrhea effects.
Although atropine treats bradycardia (slow heart rate) in emergency settings, it can cause paradoxical heart rate slowing when given at very low doses (i.e. <0.5 mg),[21] presumably as a result of central action in the CNS.[22] One proposed mechanism for atropine's paradoxical bradycardia effect at low doses involves blockade of inhibitory presynaptic muscarinic autoreceptors, thereby blocking a system that inhibits the parasympathetic response.[23]
Atropine is incapacitating at doses of 10 to 20 mg per person. Its LD50 is estimated to be 453 mg per person (by mouth) with a probit slope of 1.8.[24]
The antidote to atropine is physostigmine or pilocarpine.
A common mnemonic used to describe the physiologic manifestations of atropine overdose is: "hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter".[25]  These associations reflect the specific changes of warm, dry skin from decreased sweating, blurry vision, decreased lacrimation, vasodilation, and central nervous system effects on muscarinic receptors, type 4 and 5. This set of symptoms is known as anticholinergic toxidrome, and may also be caused by other drugs with anticholinergic effects, such as hyoscine hydrobromide (scopolamine), diphenhydramine, phenothiazine antipsychotics and benztropine.[26]

Contraindications[edit]
It is generally contraindicated in people with glaucoma, pyloric stenosis, or prostatic hypertrophy, except in doses ordinarily used for preanesthesia.[27]

Chemistry[edit]
This article needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed.Find sources: "Atropine" – news · newspapers · books · scholar · JSTOR  (January 2022)
Atropine, a tropane alkaloid, is an enantiomeric mixture of d-hyoscyamine and l-hyoscyamine, with most of its physiological effects due to l-hyoscyamine. Its pharmacological effects are due to binding to muscarinic acetylcholine receptors. It is an antimuscarinic agent. Significant levels are achieved in the CNS within 30 minutes to 1 hour and disappears rapidly from the blood with a half-life of 2 hours. About 60% is excreted unchanged in the urine, most of the rest appears in urine as hydrolysis and conjugation products. Noratropine (24%), atropine-N-oxide (15%), tropine (2%) and tropic acid (3%) appear to be the major metabolites, while 50% of the administered dose is excreted as apparently unchanged atropine. No conjugates were detectable. Evidence that atropine is present as (+)-hyoscyamine was found, suggesting that stereoselective metabolism of atropine probably occurs.[28] Effects on the iris and ciliary muscle may persist for longer than 72 hours.
The most common atropine compound used in medicine is atropine sulfate (monohydrate) (C17H23NO3)2·H2SO4·H2O, the full chemical name is 1α H, 5α H-Tropan-3-α ol (±)-tropate(ester), sulfate monohydrate.

Pharmacology[edit]
This article needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed.Find sources: "Atropine" – news · newspapers · books · scholar · JSTOR  (January 2022)
In general, atropine counters the "rest and digest" activity of glands regulated by the parasympathetic nervous system. This occurs because atropine is a competitive, reversible antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system).
Atropine is a competitive antagonist of the muscarinic acetylcholine receptor types M1, M2, M3, M4 and M5.[29] It is classified as an anticholinergic drug (parasympatholytic).
In cardiac uses, it works as a nonselective muscarinic acetylcholinergic antagonist, increasing firing of the sinoatrial node (SA) and conduction through the atrioventricular node (AV) of the heart, opposes the actions of the vagus nerve, blocks acetylcholine receptor sites, and decreases bronchial secretions.
In the eye, atropine induces mydriasis by blocking contraction of the circular pupillary sphincter muscle, which is normally stimulated by acetylcholine release, thereby allowing the radial iris dilator muscle to contract and dilate the pupil. Atropine induces cycloplegia by paralyzing the ciliary muscles, whose action inhibits accommodation to allow accurate refraction in children, helps to relieve pain associated with iridocyclitis, and treats ciliary block (malignant) glaucoma.
The vagus (parasympathetic) nerves that innervate the heart release acetylcholine (ACh) as their primary neurotransmitter. ACh binds to muscarinic receptors (M2) that are found principally on cells comprising the sinoatrial (SA) and atrioventricular (AV) nodes. Muscarinic receptors are coupled to the Gi subunit; therefore, vagal activation decreases cAMP. Gi-protein activation also leads to the activation of KACh channels that increase potassium efflux and hyperpolarizes the cells.
Increases in vagal activities to the SA node decreases the firing rate of the pacemaker cells by decreasing the slope of the pacemaker potential (phase 4 of the action potential); this decreases heart rate (negative chronotropy). The change in phase 4 slope results from alterations in potassium and calcium currents, as well as the slow-inward sodium current that is thought to be responsible for the pacemaker current (If). By hyperpolarizing the cells, vagal activation increases the cell's threshold for firing, which contributes to the reduction in the firing rate. Similar electrophysiological effects also occur at the AV node; however, in this tissue, these changes are manifested as a reduction in impulse conduction velocity through the AV node (negative dromotropy). In the resting state, there is a large degree of vagal tone on the heart, which is responsible for low resting heart rates.
There is also some vagal innervation of the atrial muscle, and to a much lesser extent, the ventricular muscle. Vagus activation, therefore, results in modest reductions in atrial contractility (inotropy) and even smaller decreases in ventricular contractility.
Muscarinic receptor antagonists bind to muscarinic receptors thereby preventing ACh from binding to and activating the receptor. By blocking the actions of ACh, muscarinic receptor antagonists very effectively block the effects of vagal nerve activity on the heart. By doing so, they increase heart rate and conduction velocity.

History[edit]
  Atropa belladonna
The name atropine was coined in the 19th century, when pure extracts from the belladonna plant Atropa belladonna were first made.[30] The medicinal use of preparations from plants in the nightshade family is much older however. Mandragora (mandrake) was described by Theophrastus in the fourth century B.C. for treatment of wounds, gout, and sleeplessness, and as a love potion. By the first century A.D. Dioscorides recognized wine of mandrake as an anaesthetic for treatment of pain or sleeplessness, to be given prior to surgery or cautery.[25]  The use of nightshade preparations for anesthesia, often in combination with opium, persisted throughout the Roman and Islamic Empires and continued in Europe until superseded in the 19th century by modern anesthetics.[citation needed]
Atropine-rich extracts from the Egyptian henbane plant (another nightshade) were used by Cleopatra in the last century B.C. to dilate the pupils of her eyes, in the hope that she would appear more alluring. Likewise in the Renaissance, women used the juice of the berries of the nightshade Atropa belladonna to enlarge their pupils for cosmetic reasons. This practice resumed briefly in the late nineteenth and early twentieth century in Paris.[citation needed]
The pharmacological study of belladonna extracts was begun by the German chemist Friedlieb Ferdinand Runge (1795–1867). In 1831, the German pharmacist Heinrich F. G. Mein (1799-1864)[31] succeeded in preparing a pure crystalline form of the active substance, which was named atropine.[32]
[33] The substance was first synthesized by German chemist Richard Willstätter in 1901.[34]

Natural sources[edit]
Atropine is found in many members of the family Solanaceae. The most commonly found sources are Atropa belladonna (the deadly nightshade), Datura innoxia, D. wrightii,  D. metel, and D. stramonium. Other sources include members of the genera Brugmansia (angel's trumpets) and Hyoscyamus.[citation needed]

Synthesis[edit]
Atropine can be synthesized by the reaction of tropine with tropic acid in the presence of hydrochloric acid.

Biosynthesis[edit]
  Biosynthesis of atropine starting from L-Phenylalanine
The biosynthesis of atropine starting from l-phenylalanine first undergoes a transamination forming phenylpyruvic acid which is then reduced to phenyl-lactic acid.[35]  Coenzyme A then couples phenyl-lactic acid with tropine forming littorine, which then undergoes a radical rearrangement initiated with a P450 enzyme forming hyoscyamine aldehyde.[35]  A dehydrogenase then reduces the aldehyde to a primary alcohol making (−)-hyoscyamine, which upon racemization forms atropine.[35]

Name[edit]
The species name "belladonna" ('beautiful woman' in Italian) comes from the original use of deadly nightshade to dilate the pupils of the eyes for cosmetic effect. Both atropine and the genus name for deadly nightshade derive from Atropos, one of the three Fates who, according to Greek mythology, chose how a person was to die.[25]

See also[edit]
Apoatropine
Mark I Nerve Agent Antidote Kit
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Rafinesque CS (1828). Medical Flora; Or, Manual of the Medical Botany of the United States of ... - Constantine Samuel Rafinesque - Internet Archive. Atkinson & Alexander. p. 148. Retrieved 2012-11-07.

^ a b c Barash PG (2009). Clinical anesthesia (6th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 525. ISBN 9780781787635. Archived from the original on 2015-11-24.

^ a b c d e f g "Atropine". The American Society of Health-System Pharmacists. Archived from the original on 2015-07-12. Retrieved Aug 13, 2015.

^ Hamilton RJ, Duffy AN, Stone D, Spencer A (2014). Tarascon pharmacopoeia (15 ed.). p. 386. ISBN 9781284056716. Archived from the original on 2015-10-02.

^ "Amblyopia (Lazy Eye)". National Eye Institute. 2019-07-02. Retrieved 2020-01-31. Putting special eye drops in the stronger eye. A once-a-day drop of the drug atropine can temporarily blur near vision, which forces the brain to use the other eye. For some children, this treatment works as well as an eye patch, and some parents find it easier to use (for example, because young children may try to pull off eye patches).

^ a b "Atropine Pregnancy and Breastfeeding Warnings". Archived from the original on 6 September 2015. Retrieved 14 August 2015.

^ Brust JC (2004). Neurological aspects of substance abuse (2 ed.). Philadelphia: Elsevier. p. 310. ISBN 9780750673136. Archived from the original on 2015-10-02.

^ Ainsworth S (2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 94. ISBN 9781118819593. Archived from the original on 2015-10-02.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.

^ Hamilton RJ (2014). Tarascon pharmacopoeia (15 ed.). p. 386. ISBN 9781284056716. Archived from the original on 2015-10-02.

^ Georgievski Z, Koklanis K, Leone J (2008). "Fixation behavior in the treatment of amblyopia using atropine". Clinical and Experimental Ophthalmology. 36 (Suppl 2): A764–A765.

^ Li T, Qureshi R, Taylor K (August 2019). "Conventional occlusion versus pharmacologic penalization for amblyopia". The Cochrane Database of Systematic Reviews. 8: CD006460. doi:10.1002/14651858.CD006460.pub3. PMC 6713317. PMID 31461545.

^ Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, Twelker JD (13 Jan 2020). "Interventions to slow progression of myopia in children". Cochrane Database Syst Rev. 1 (9): CD004916. doi:10.1002/14651858.CD004916.pub4. PMC 6984636. PMID 31930781.

^ a b Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L (June 2017). "Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis". JAMA Ophthalmology. 135 (6): 624–630. doi:10.1001/jamaophthalmol.2017.1091. PMC 5710262. PMID 28494063.

^ Fricke T, Hurairah H, Huang Y, Ho SM (2019). "Pharmacological interventions in myopia management". Community Eye Health. 32 (105): 21–22. PMC 6688412. PMID 31409953.

^ Field JM, Hazinski MF, Sayre MR, Chameides L, Schexnayder SM, Hemphill R,  et al. (November 2010). "Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S640-56. doi:10.1161/CIRCULATIONAHA.110.970889. PMID 20956217.

^ * Bledsoe BE, Porter RS, Cherry RA (2004). "Ch. 3". Intermediate Emergency Care. Upper Saddle River, NJ: Pearson Prentice Hill. p. 260. ISBN 0-13-113607-0.

^ de Caen AR, Berg MD, Chameides L, Gooden CK, Hickey RW, Scott HF,  et al. (November 2015). "Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 132 (18 Suppl 2): S526-42. doi:10.1161/cir.0000000000000266. PMC 6191296. PMID 26473000.

^ "Death Rattle and Oral Secretions, 2nd ed". eperc.mcw.edu. Archived from the original on 2014-04-14. Retrieved 2019-10-20.

^ Yumuk, P. F.; Aydin, S. Z.; Dane, F.; Gumus, M.; Ekenel, M.; Aliustaoglu, M.; Karamanoglu, A.; Sengoz, M.; Turhal, S. N. (2004-11-01). "The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients". International Journal of Colorectal Disease. 19 (6): 609–610. doi:10.1007/s00384-004-0613-5. ISSN 1432-1262.

^ "Atropine Drug Information". uptodate.com. Archived from the original on 2014-02-20. Retrieved 2014-02-02.

^ * Rang HP, Dale MM, Ritter JM, Flower RJ (2007). "Ch. 10". Rang and Dale's Pharmacology. Elsevier Churchill Livingstone. p. 153. ISBN 978-0-443-06911-6.

^ Laurence B (2010). Goodman & Gilman's Pharmacological Basis of Therapeutics, 12th Edition. McGraw-Hill. ISBN 978-0-07-162442-8.

^ * Goodman E (2010).  Ketchum J, Kirby R (eds.). Historical Contributions to the Human Toxicology of Atropine. Eximdyne. p. 120. ISBN 978-0-9677264-3-4.

^ a b c Holzman RS (July 1998). "The legacy of Atropos, the fate who cut the thread of life". Anesthesiology. 89 (1): 241–9. doi:10.1097/00000542-199807000-00030. PMID 9667313. S2CID 28327277. Retrieved 2007-05-21. citing J. Arena, Poisoning: Toxicology-Symptoms-Treatments, 3rd edition. Springfield, Charles C. Thomas, 1974, p 345

^ Szajewski J (1995). "Acute anticholinergic syndrome". IPCS Intox Databank. Archived from the original on 2 July 2007. Retrieved 2007-05-22.

^ "ATROPINE SULFATE". dailymed.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 30 October 2019.

^ Van der Meer MJ, Hundt HK, Müller FO (October 1986). "The metabolism of atropine in man". The Journal of Pharmacy and Pharmacology. 38 (10): 781–4. doi:10.1111/j.2042-7158.1986.tb04494.x. PMID 2879005. S2CID 27306334.

^ Rang, Dale, Ritter and More (2003). Pharmacology. Elsevier. p. 139.{{cite book}}:  CS1 maint: uses authors parameter (link)

^ Goodman and Gilman's Pharmacological Basis of Therapeutics, q.v. "Muscarinic receptor antagonists - History", p. 163 of the 2001 edition.

^ "Heinrich Friedrich Georg Mein". ostfriesischelandschaft.de (in German). Archived from the original on 2013-05-11. Retrieved 2019-10-20.{{cite web}}:  CS1 maint: unfit URL (link)

^ Heinrich Friedrich Georg Mein (1833). "Ueber die Darstellung des Atropins in weissen Kristallen" [On the preparation of atropine as white crystals]. Annalen der Pharmacie (in German). Vol. 6 (1 ed.). pp. 67–72.

^ Atropine was also independently isolated in 1833 by Geiger and Hesse:
Geiger, Hesse (1833). "Darstellung des Atropins" [Preparation of atropine]. Annalen der Pharmacie (in German). Vol. 5. pp. 43–81.
Geiger, Hesse (1833). "Fortgesetzte Versuche über Atropin" [Continued experiments on atropine]. Annalen der Pharmacie (in German). Vol. 6. pp. 44–65.

^ See:
Willstätter R (1901). "Synthese des Tropidins" [Synthesis of tropidine]. Berichte der Deutschen Chemischen Gesellschaft zu Berlin (in German). 34: 129–144. doi:10.1002/cber.19010340124. Archived from the original on 2013-03-01.
Willstätter R (1901). "Umwandlung von Tropidin in Tropin" [Conversion of tropidine into tropine]. Berichte der Deutschen Chemischen Gesellschaft zu Berlin (in German). 34 (2): 3163–3165. doi:10.1002/cber.190103402289. Archived from the original on 2013-01-26.

^ a b c Dewick PM (9 March 2009). Medicinal Natural Products: A Biosynthetic Approach (3rd ed.). Chichester: A John Wiley & Sons. ISBN 978-0-470-74167-2.


External links[edit]
 Media related to Atropine at Wikimedia Commons
"Atropine". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAncient anaesthesiaPlants / animals
Aconitum (aconite)
Atropa belladonna (belladonna)
Cannabis
medical use
Castoreum
Coca
Conium (hemlock)
Datura innoxia (thorn-apple)
Datura metel (devil's trumpet)
Hyoscyamus niger (henbane)
Lactucarium
Mandragora officinarum (mandrake)
Opium
Saussurea (saw-wort)
Willow
People
Abulcasis
Avenzoar
Avicenna
Celsus
Dioscorides
Galen
Hippocrates
Rhazes
Sabuncuoğlu
Sushrutha
Theophrastus
Zhang
Compounds
Aconitine
Atropine
Cocaine
Coniine
Hyoscine
Δ9-THC
Hyoscyamine
Morphine
Salicylate

vteDrugs for functional gastrointestinal disorders (A03)Drugs for functional bowel disordersAntimuscarinicsTertiary amino group
Oxyphencyclimine
Camylofin
Mebeverine
Trimebutine
Rociverine
Dicycloverine
Dihexyverine
Difemerine
Piperidolate
Quaternary ammonium compounds
Benzilone
Mepenzolate
Pipenzolate
Glycopyrronium
Oxyphenonium
Penthienate
Methantheline
Propantheline
Otilonium
Tridihexethyl
Isopropamide
Hexocyclium
Poldine
Bevonium
Diphemanil
Tiemonium
Prifinium
Timepidium
Fenpiverinium
Phosphodiesterase inhibitors
Papaverine
Drotaverine
Moxaverine
Acting on serotonin receptors
5-HT3 antagonists
Alosetron
Cilansetron
5-HT4 agonists
Mosapride
Other
Alverine
Caroverine
Chlorbenzoxamine
Diisopromine
Dimethylaminopropionylphenothiazine
Fenpiprane
Fenoverine
Idanpramine
Isometheptene
Mentha piperita
Phloroglucinol
Pinaverium bromide
Proxazole
Silicones
Simeticone
Tiropramide
Trepibutone
Trimethyldiphenylpropylamine
Belladonna and derivatives (antimuscarinics)
Tertiary amines: Atropine
Hyoscyamine
Quaternary ammonium compounds:
Scopolamine
Butylscopolamine
Methylscopolamine
Methylatropine
Fentonium bromide
Cimetropium bromide
Propulsives
Primarily dopamine antagonists
Metoclopramide/Bromopride
Clebopride
Domperidone
Alizapride
5-HT4 agonists
Cinitapride
Cisapride

vteEmergency medicineEmergency medicine
Emergency department
Emergency medical services
Emergency nursing
Emergency psychiatry
Golden hour
Medical emergency
International emergency medicine
Pediatric emergency medicine
Pre-hospital emergency medicine
Major trauma
Trauma center
Triage
Equipment
Bag valve mask (BVM)
Chest tube
Defibrillation (AED
ICD)
Electrocardiogram (ECG/EKG)
Intraosseous infusion (IO)
Intravenous therapy (IV)
Tracheal intubation
Laryngeal tube
Combitube
Nasopharyngeal airway (NPA)
Oropharyngeal airway (OPA)
Pocket mask
Drugs
Adenosine
Amiodarone
Atropine
Dopamine
Epinephrine / Adrenaline
Naloxone
Magnesium sulfate
Sodium bicarbonate
Organisations
International Federation for Emergency Medicine (International Conference on Emergency Medicine)
American College of Emergency Physicians
Australasian College for Emergency Medicine
Canadian Association of Emergency Physicians
Royal College of Emergency Medicine
European Society for Emergency Medicine
Asian Society for Emergency Medicine
American Academy of Emergency Medicine
Courses / Life support
First aid
Cardiopulmonary resuscitation (CPR)
Mouth-to-mouth resuscitation
Basic life support (BLS)
Advanced cardiac life support (ACLS)
Advanced trauma life support (ATLS)
Neonatal Resuscitation Program (NRP)
Acute Care of at-Risk Newborns (ACoRN)
Pediatric basic life support (PBLS)
Pediatric Advanced Life Support (PALS)
Advanced Life Support in Obstetrics (ALSO)
Care of the Critically Ill Surgical Patient (CCrISP)
Scoring systems
NACA score
Injury Severity Score

 Category
 Outline

vteHallucinogensPsychedelics(5-HT2Aagonists)Benzofurans
2C-B-FLY
2CBFly-NBOMe
5-MeO-BFE
5-MeO-DiBF
Bromo-DragonFLY
F-2
F-22
TFMFly
Lyserg‐amides
1B-LSD
1cP-LSD
1P-ETH-LAD
1P-LSD
1cP-AL-LAD
1cP-MiPLA
1V-LSD
2-Butyllysergamide
3-Pentyllysergamide
AL-LAD
ALD-52
BU-LAD
Diallyllysergamide
Dimethyllysergamide
ECPLA
Ergometrine
ETH-LAD
IP-LAD
LAE-32
LAMPA
LPD-824
LSA
LSD
LSD-Pip
LSH
LSM-775
LSZ
Methylergometrine
MIPLA
Methysergide
MLD-41
PARGY-LAD
PRO-LAD
Phenethyl‐amines2C-x
2C-B
2C-B-AN
2C-Bn
2C-Bu
2C-C
2C-CN
2C-CP
2C-D
2C-E
2C-EF
2C-F
2C-G
2C-G-1
2C-G-2
2C-G-3
2C-G-4
2C-G-5
2C-G-6
2C-G-N
2C-H
2C-I
2C-iP
2C-N
2C-NH2
2C-O
2C-O-4
2C-P
2C-Ph
2C-SE
2C-T
2C-T-2
2C-T-3
2C-T-4
2C-T-5
2C-T-6
2C-T-7
2C-T-8
2C-T-9
2C-T-10
2C-T-11
2C-T-12
2C-T-13
2C-T-14
2C-T-15
2C-T-16
2C-T-17
2C-T-18
2C-T-19
2C-T-20
2C-T-21
2C-T-22
2C-T-22.5
2C-T-23
2C-T-24
2C-T-25
2C-T-27
2C-T-28
2C-T-30
2C-T-31
2C-T-32
2C-T-33
2C-TFE
2C-TFM
2C-YN
2C-V
    25x-NBx25x-NB
25B-NB
25C-NB
25x-NB3OMe
25B-NB3OMe
25C-NB3OMe
25D-NB3OMe
25E-NB3OMe
25H-NB3OMe
25I-NB3OMe
25N-NB3OMe
25P-NB3OMe
25T2-NB3OMe
25T4-NB3OMe
25T7-NB3OMe
25TFM-NB3OMe
25x-NB4OMe
25B-NB4OMe
25C-NB4OMe
25D-NB4OMe
25E-NB4OMe
25H-NB4OMe
25I-NB4OMe
25N-NB4OMe
25P-NB4OMe
25T2-NB4OMe
25T4-NB4OMe
25T7-NB4OMe
25TFM-NB4OMe
25x-NBF
25B-NBF
25C-NBF
25D-NBF
25E-NBF
25H-NBF
25I-NBF
25P-NBF
25T2-NBF
25T7-NBF
25TFM-NBF
25x-NBMD
25B-NBMD
25C-NBMD
25D-NBMD
25E-NBMD
25F-NBMD
25H-NBMD
25I-NBMD
25P-NBMD
25T2-NBMD
25T7-NBMD
25TFM-NBMD
25x-NBOH
25B-NBOH
25C-NBOH
25CN-NBOH
25D-NBOH
25E-NBOH
25F-NBOH
25H-NBOH
25I-NBOH
25P-NBOH
25T2-NBOH
25T7-NBOH
25TFM-NBOH
25x-NBOMe
25B-NBOMe
25C-NBOMe
25CN-NBOMe
25D-NBOMe
25E-NBOMe
25F-NBOMe
25G-NBOMe
25H-NBOMe
25I-NBOMe
25iP-NBOMe
25N-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T4-NBOMe
25T7-NBOMe
25TFM-NBOMe
Atypical structures
25B-N1POMe
25B-NAcPip
25B-NB23DM
25B-NB25DM
25C-NBCl
25C-NBOEt
25C-NBOiPr
25I-N2Nap1OH
25I-N3MT2M
25I-N4MT3M
25I-NB34MD
25I-NBAm
25I-NBBr
25I-NBMeOH
25I-NBTFM
2CBCB-NBOMe
2CBFly-NBOMe
4-EA-NBOMe
5-APB-NBOMe
5MT-NBOMe
C30-NBOMe
DOB-NBOMe
DOI-NBOMe
FECIMBI-36
MDPEA-NBOMe
NBOMe-escaline
NBOMe-mescaline
ZDCM-04
25x-NMx
25B-NMe7BF
25B-NMe7BT
25B-NMe7Box
25B-NMe7DHBF
25B-NMe7Ind
25B-NMe7Indz
25B-NMePyr
25I-NMe7DHBF
25I-NMeFur
25I-NMeTHF
25I-NMeTh

3C-x
3C-AL
3C-BZ
3C-DFE
3C-E
3C-MAL
3C-P
4C-x
4C-B
4C-C
4C-D
4C-E
4C-I
4C-N
4C-P
4C-T-2
DOx
DOT
DOB
DOC
DOEF
DOET
DOF
DOI
DOiPR
DOM
DON
DOPR
DOTFM
MEM
HOT-x
HOT-2
HOT-7
HOT-17
MDxx
DMMDA
DMMDA-2
Lophophine
MDA
MDAI
MDBZ
MDMA
MMDA
MMDA-2
MMDA-3a
MMDMA
Mescaline (subst.)
2-Bromomescaline
3-TE
4-TE
3-TM
4-TM
Allylescaline
Asymbescaline
Buscaline
Cyclopropylmescaline
Difluoromescaline
Difluoroescaline
Escaline
Fluoroproscaline
Isobuscaline
Isoproscaline
Jimscaline
Mescaline
Metaescaline
Methallylescaline
Proscaline
Thioproscaline
Trifluoroescaline
Trifluoromescaline
TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
2C-B-BUTTERFLY
2C-B-DragonFLY
2C-B-DragonFLY-NBOH
2C-B-FLY-NB2EtO5Cl
2CB-5-hemifly
2CB-Ind
2CD-5EtO
2-TOET
5-TOET
2-TOM
5-TOM
BOB
BOD
βk-2C-B
βk-2C-I
DESOXY
DMCPA
DMBMPP
DOB-FLY
Fenfluramine
Ganesha
Macromerine
MMA
TCB-2
TOMSO
Piperazines
2C-B-PP
BZP
pFPP
Tryptaminesalpha-alkyltryptamines
4,5-DHP-α-MT
5-MeO-α-ET
5-MeO-α-MT
α-ET
α-MT
x-DALT
(Daltocin) 4-HO-DALT
(Daltacetin) 4-AcO-DALT
5-MeO-DALT
DALT
x-DET
(Ethacetin) 4-AcO-DET
(Ethocin) 4-HO-DET
5-MeO-DET
(T-9) DET
(Ethocybin) 4-PO-DET
x-DiPT
(Ipracetin) 4-AcO-DiPT
(Iprocin) 4-HO-DiPT
5-MeO-DiPT
DiPT
x-DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N,N-TMT
5-MeO-4,N,N-TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N,N-TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x-DPT
(Depracetin) 4-AcO-DPT
(Deprocin) 4-HO-DPT
5-MeO-DPT
(The Light) DPT
Ibogaine-related
18-MAC
18-MC
Coronaridine
Ibogaine
Ibogamine
ME-18-MC
Noribogaine
Tabernanthine
Voacangine
x-MET
(Metocin) 4-HO-MET
(Metocetin) 4-AcO-MET
5-MeO-MET
MET
x-MiPT
(Mipracetin) 4-AcO-MiPT
(Miprocin) 4-HO-MiPT
5-Me-MiPT
(Moxy) 5-MeO-MiPT
MiPT
Others
4-HO-DBT
4-HO-EPT
4-HO-McPT
(Lucigenol) 4-HO-MPMI
(Meprocin) 4-HO-MPT
5-MeO-EiPT
5-MeO-MALT
5-MeO-MPMI
Aeruginascin
Baeocystin
DBT
DCPT
EiPT
EPT
MPT
PiPT
Others
AL-38022A
ALPHA
Dimemebfe
Efavirenz
Glaucine
Lorcaserin
M-ALPHA
RH-34Also empathogens in general (e. g.: 5-APB, 5-MAPB, 6-APB and other substituted benzofurans).
Dissociatives(NMDARantagonists)Arylcyclo‐hexylaminesKetamine-related
2-Fluorodeschloroketamine
Arketamine ((R)-ketamine)
Deschloroketamine
Ethketamine (N-Ethylnorketamine)
Esketamine ((S)-ketamine)
Ketamine
Methoxetamine
Methoxmetamine
Methoxyketamine
MXiPr
Norketamine
Tiletamine
PCP-related
2'-Oxo-PCE
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
BDPC
Dieticyclidine (PCDE)
Eticyclidine (PCE)
PCPr
Phencyclidine (PCP)
Rolicyclidine (PCPy)
Tenocyclidine (TCP)
Others
BTCP
Gacyclidine
PRE-084
Diarylethylamines
Diphenidine
Ephenidine
Fluorolintane
Methoxphenidine
Morphinans
Dextrallorphan
Dextromethorphan
Dextrorphan
Racemethorphan
Racemorphan
Others
2-EMSB
2-MDP
8A-PDHQ
Aptiganel
Budipine
Delucemine
Dexoxadrol
Dizocilpine
Etoxadrol
Herkinorin
Ibogaine
Midafotel
NEFA
Neramexane
Nitrous oxide
Noribogaine
Perzinfotel
RB-64
Remacemide
Selfotel
Xenon
Deliriants(mAChRantagonists)
Atropine
Benactyzine
Benzatropine
Benzydamine
Biperiden
BRN-1484501
Brompheniramine
BZ
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Chloropyramine
Chlorphenamine
Clemastine
CS-27349
Cyclizine
Cyproheptadine
Dicycloverine
Dimenhydrinate
Diphenhydramine
Ditran
Doxylamine
EA-3167
EA-3443
EA-3580
EA-3834
Elemicin
Flavoxate
Hyoscyamine
JB-318
JB-336
Meclozine
Mepyramine
Myristicin
Orphenadrine
Oxybutynin
Pheniramine
Phenyltoloxamine
Procyclidine
Promethazine
Scopolamine
Tolterodine
Trihexyphenidyl
Tripelennamine
Triprolidine
WIN-2299
OthersCannabinoids(CB1 agonists)Natural
Salvinorin A
THC (Dronabinol)
THCV
SyntheticAM-x
AM-087
AM-251
AM-279
AM-281
AM-356
AM-374
AM-381
AM-404
AM-411
AM-630
AM-661
AM-678
AM-679
AM-694
AM-735
AM-855
AM-881
AM-883
AM-905
AM-906
AM-919
AM-926
AM-938
AM-1116
AM-1172
AM-1220
AM-1221
AM-1235
AM-1241
AM-1248
AM-1710
AM-1714
AM-1902
AM-2201
AM-2212
AM-2213
AM-2232
AM-2233
AM-2389
AM-3102
AM-4030
AM-4054
AM-4056
AM-4113
AM-6545
CP x
CP 47,497
CP 55,244
CP 55,940
(±)-CP 55,940
(+)-CP 55,940
(-)-CP 55,940
HU-x
HU-210
HU-211
HU-239
HU-243
HU-308
HU-320
HU-331
HU-336
HU-345
JWH-x
JWH-007
JWH-015
JWH-018
JWH-019
JWH-030
JWH-047
JWH-048
JWH-051
JWH-057
JWH-073
JWH-081
JWH-098
JWH-116
JWH-120
JWH-122
JWH-133
JWH-139
JWH-147
JWH-148
JWH-149
JWH-149
JWH-161
JWH-164
JWH-166
JWH-167
JWH-171
JWH-175
JWH-176
JWH-181
JWH-182
JWH-184
JWH-185
JWH-192
JWH-193
JWH-194
JWH-195
JWH-196
JWH-197
JWH-198
JWH-199
JWH-200
JWH-203
JWH-205
JWH-210
JWH-210
JWH-213
JWH-220
JWH-229
JWH-234
JWH-249
JWH-250
JWH-251
JWH-253
JWH-258
JWH-300
JWH-302
JWH-307
JWH-336
JWH-350
JWH-359
JWH-387
JWH-398
JWH-424
Misc. designer cannabinoids
4-HTMPIPO
5F-AB-FUPPYCA
5F-AB-PINACA
5F-ADB
5F-ADB-PINACA
5F-ADBICA
5F-AMB
5F-APINACA
5F-CUMYL-PINACA
5F-NNE1
5F-PB-22
5F-SDB-006
A-796,260
A-836,339
AB-001
AB-005
AB-CHFUPYCA
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADAMANTYL-THPINACA
ADB-CHMINACA
ADB-FUBINACA
ADB-PINACA
ADBICA
ADSB-FUB-187
AMB-FUBINACA
APICA
APINACA
APP-FUBINACA
CB-13
CUMYL-PICA
CUMYL-PINACA
CUMYL-THPINACA
DMHP
EAM-2201
FAB-144
FDU-PB-22
FUB-144
FUB-APINACA
FUB-JWH-018
FUB-PB-22
FUBIMINA
JTE 7-31
JTE-907
Levonantradol
MDMB-CHMICA
MDMB-CHMINACA
MDMB-FUBINACA
MEPIRAPIM
MAM-2201
MDA-19
MN-18
MN-25
NESS-0327
NESS-040C5
Nabilone
Nabitan
NM-2201
NNE1
Org 28611
Parahexyl
PTI-1
PTI-2
PX-1
PX-2
PX-3
QUCHIC
QUPIC
RCS-4
RCS-8
SDB-005
SDB-006
STS-135
THC-O-acetate
THC-O-phosphate
THJ-018
THJ-2201
UR-144
WIN 55,212-2
XLR-11
D2 agonists
Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
LSD
Memantine
Nuciferine
Pergolide
Phenethylamine
Piribedil
Pramipexole
Ropinirole
Rotigotine
Salvinorin AAlso indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).
GABAAenhancers
CI-966
Eszopiclone
Ibotenic acid
Muscimol (Amanita muscaria)
Zaleplon
Zolpidem
Zopiclone
Inhalants(Mixed MOA)
Aliphatic hydrocarbons
Butane
Gasoline
Kerosene
Propane
Aromatic hydrocarbons
Toluene
Ethers
Diethyl ether
Enflurane
Haloalkanes
Chlorofluorocarbons
Chloroform
κOR agonists
2-EMSB
Alazocine
Bremazocine
Butorphan
Butorphanol
Cyclazocine
Cyclorphan
Cyprenorphine
Diprenorphine
Enadoline
Herkinorin
Heroin
HZ-2
Ibogaine
Ketazocine
Levallorphan
Levomethorphan
Levorphanol
LPK-26
Metazocine
Morphine
Nalbuphine
Nalmefene
Nalorphine
Noribogaine
Oxilorphan
Pentazocine
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
Salvinorin A
Spiradoline
Tifluadom
U-50488
U-69,593
Xorphanol
Oneirogens
Calea zacatechichi
Silene capensis
Galantamine
Others
Glaucine
Isoaminile
Noscapine
Pukateine

vteOphthalmologicals: mydriasis and cycloplegia (S01F)Anticholinergics/antimuscarinics
Atropine
Scopolamine
Methylscopolamine
Cyclopentolate
Homatropine
Tropicamide
Sympathomimetics
Phenylephrine (+ketorolac)
Ephedrine
Ibopamine

vteDrugs used for glaucoma preparations and miosis (S01E)Sympathomimetics
Apraclonidine
Brimonidine (+timolol)
Clonidine
Dipivefrine
Epinephrine
Parasympathomimeticsmuscarinic
Aceclidine
Pilocarpine
muscarinic/nicotinic
Acetylcholine
Carbachol
acetylcholinesterase inhibitors
Demecarium
Ecothiopate
Stigmine (Fluostigmine
Neostigmine
Physostigmine)
Paraoxon
Carbonic anhydrase inhibitors/(sulfonamides)
Acetazolamide
Brinzolamide (+timolol, +brimonidine)
Diclofenamide
Dorzolamide (+timolol)
Methazolamide
Beta blocking agents
Befunolol
Betaxolol
Carteolol
Levobunolol
Metipranolol
Timolol
Mepindolol
Prostaglandin analogues (F2α)
Bimatoprost (+timolol)
Latanoprost (+timolol)
Tafluprost
Travoprost (+timolol)
Unoprostone
Other agents
Dapiprazole
Guanethidine
Netarsudil (+latanoprost)
Ripasudil

vteMuscarinic acetylcholine receptor modulatorsmAChRsAgonists
77-LH-28-1
AC-42
AC-260,584
Aceclidine
Acetylcholine
AF30
AF150(S)
AF267B
Alvameline
AQRA-741
Arecoline
Bethanechol
Bevonium
Butyrylcholine
Carbachol
CDD-0034
CDD-0078
CDD-0097
CDD-0098
CDD-0102
Cevimeline
Choline
cis-Dioxolane
Clozapine
Desmethylclozapine (norclozapine)
Ethoxysebacylcholine
Itameline
LY-593,039
L-689,660
LY-2,033,298
McNA343
Methacholine
Milameline
Muscarine
NGX-267
Ocvimeline
Oxotremorine
PD-151,832
Pilocarpine
RS86
Sabcomeline
SDZ 210-086
Sebacylcholine
Suberyldicholine
Talsaclidine
Tazomeline
Thiopilocarpine
Vedaclidine
VU-0029767
VU-0090157
VU-0152099
VU-0152100
VU-0238429
WAY-132,983
Xanomeline
YM-796
Antagonists
3-Quinuclidinyl benzilate
4-DAMP
Aclidinium bromide (+formoterol)
Abediterol
AF-DX 250
AF-DX 384
Ambutonium bromide
Anisodamine
Anisodine
Antihistamines (first-generation) (e.g., brompheniramine, buclizine, captodiame, chlorphenamine (chlorpheniramine), cinnarizine, clemastine, cyproheptadine, dimenhydrinate, dimetindene, diphenhydramine, doxylamine, meclizine, mequitazine, perlapine, phenindamine, pheniramine, phenyltoloxamine, promethazine, propiomazine, triprolidine)
AQ-RA 741
Atropine
Atropine methonitrate
Atypical antipsychotics (e.g., clozapine, fluperlapine, olanzapine (+fluoxetine), rilapine, quetiapine, tenilapine, zotepine)
Benactyzine
Benzatropine (benztropine)
Benzilone
Benzilylcholine mustard
Benzydamine
BIBN 99
Biperiden
Bornaprine
Camylofin
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Caramiphen
Cimetropium bromide
Clidinium bromide
Cloperastine
CS-27349
Cyclobenzaprine
Cyclopentolate
Darifenacin
DAU-5884
Desfesoterodine
Dexetimide
DIBD
Dicycloverine (dicyclomine)
Dihexyverine
Difemerine
Diphemanil metilsulfate
Ditran
Drofenine
EA-3167
EA-3443
EA-3580
EA-3834
Emepronium bromide
Etanautine
Etybenzatropine (ethybenztropine)
Fenpiverinium
Fentonium bromide
Fesoterodine
Flavoxate
Glycopyrronium bromide (+beclometasone/formoterol, +indacaterol)
Hexahydrodifenidol
Hexahydrosiladifenidol
Hexbutinol
Hexocyclium
Himbacine
HL-031,120
Homatropine
Imidafenacin
Ipratropium bromide (+salbutamol)
Isopropamide
J-104,129
Hyoscyamine
Mamba toxin 3
Mamba toxin 7
Mazaticol
Mebeverine
Meladrazine
Mepenzolate
Methantheline
Methoctramine
Methylatropine
Methylhomatropine
Methylscopolamine
Metixene
Muscarinic toxin 7
N-Ethyl-3-piperidyl benzilate
N-Methyl-3-piperidyl benzilate
Nefopam
Octatropine methylbromide (anisotropine methylbromide)
Orphenadrine
Otenzepad (AF-DX 116)
Otilonium bromide
Oxapium iodide
Oxitropium bromide
Oxybutynin
Oxyphencyclimine
Oxyphenonium bromide
PBID
PD-102,807
PD-0298029
Penthienate
Pethidine
pFHHSiD
Phenglutarimide
Phenyltoloxamine
Pipenzolate bromide
Piperidolate
Pirenzepine
Piroheptine
Pizotifen
Poldine
Pridinol
Prifinium bromide
Procyclidine
Profenamine (ethopropazine)
Propantheline bromide
Propiverine
Quinidine
3-Quinuclidinyl thiochromane-4-carboxylate
Revefenacin
Rociverine
RU-47,213
SCH-57,790
SCH-72,788
SCH-217,443
Scopolamine (hyoscine)
Scopolamine butylbromide (hyoscine butylbromide)
Silahexacyclium
Sofpironium bromide
Solifenacin
SSRIs (e.g., femoxetine, paroxetine)
Telenzepine
Terodiline
Tetracyclic antidepressants (e.g., amoxapine, maprotiline, mianserin, mirtazapine)
Tiemonium iodide
Timepidium bromide
Tiotropium bromide
Tiquizium bromide
Tofenacin
Tolterodine
Tricyclic antidepressants (e.g., amitriptyline (+perphenazine), amitriptylinoxide, butriptyline, cidoxepin, clomipramine, desipramine, desmethyldesipramine, dibenzepin, dosulepin (dothiepin), doxepin, imipramine, lofepramine, nitroxazepine, northiaden (desmethyldosulepin), nortriptyline, protriptyline, quinupramine, trimipramine)
Tridihexethyl
Trihexyphenidyl
Trimebutine
Tripitamine (tripitramine)
Tropacine
Tropatepine
Tropicamide
Trospium chloride
Typical antipsychotics (e.g., chlorpromazine, chlorprothixene, cyamemazine (cyamepromazine), loxapine, mesoridazine, thioridazine)
Umeclidinium bromide (+vilanterol)
WIN-2299
Xanomeline
Zamifenacin
Precursors(and prodrugs)
Acetyl-coA
Adafenoxate
Choline (lecithin)
Citicoline
Cyprodenate
Dimethylethanolamine
Glycerophosphocholine
Meclofenoxate (centrophenoxine)
Phosphatidylcholine
Phosphatidylethanolamine
Phosphorylcholine
Pirisudanol
See also: Receptor/signaling modulators • Nicotinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators
Authority control General
Integrated Authority File (Germany)
National libraries
France (data)
United States

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





